EVA
RAMOS ALONSO
Profesora titular de universidad
Publicaciones (82) Publicaciones de EVA RAMOS ALONSO
2023
-
C-glycosides analogues of the okadaic acid central fragment exert neuroprotection via restoration of PP2A-phosphatase activity: A rational design of potential drugs for Alzheimer's disease targeting tauopathies
European Journal of Medicinal Chemistry, Vol. 251
-
Melatonin as Modulator for Sulfur and Nitrogen Mustard-Induced Inflammation, Oxidative Stress and DNA Damage: Molecular Therapeutics
Antioxidants, Vol. 12, Núm. 2
-
Melatonin: A multitasking indoleamine to modulate hippocampal neurogenesis
Neural Regeneration Research, Vol. 18, Núm. 3, pp. 503-505
-
Non-Excitatory Amino Acids, Melatonin, and Free Radicals: Examining the Role in Stroke and Aging
Antioxidants, Vol. 12, Núm. 10
-
POTENTIAL OF MELATONIN TO REVERSE EPIGENETIC ABERRATIONS IN ORAL CANCER: NEW FINDINGS
EXCLI Journal, Vol. 22, pp. 1280-1310
-
Redox Regulation of Microglial Inflammatory Response: Fine Control of NLRP3 Inflammasome through Nrf2 and NOX4
Antioxidants, Vol. 12, Núm. 9
-
Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review
Pharmaceutics, Vol. 15, Núm. 6
2022
-
Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
Cellular and Molecular Neurobiology, Vol. 42, Núm. 3, pp. 489-500
-
Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout
Journal of Medicinal Chemistry, Vol. 65, Núm. 8, pp. 6250-6260
2021
-
In Silico Prediction of the Toxic Potential of Neuroprotective Bifunctional Molecules Based on Chiral N-Propargyl-1,2-amino Alcohol Derivatives
Chemical Research in Toxicology, Vol. 34, Núm. 5, pp. 1245-1249
-
The coronavirus disease 2019 (Covid-19): Key emphasis on melatonin safety and therapeutic efficacy
Antioxidants, Vol. 10, Núm. 7
-
Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?
DISEASES, Vol. 9, Núm. 2
2020
-
Cerebral ischemia and traumatic brain injury: Protection by melatonin
Melatonin: Production, Functions and Benefits (Nova Science Publishers, Inc.), pp. 231-255
-
Highlights of ASS234: A novel and promising therapeutic agent for Alzheimer's disease therapy
Neural Regeneration Research, Vol. 15, Núm. 1, pp. 30-35
-
In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases
ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801
-
Melatonin and neurodegeneration: From neurotoxic environment to cell resilience
Advances in Molecular Toxicology (Elsevier B.V.), pp. 69-108
-
Melatonin reduces NLRP3 inflammasome activation by increasing α7 nAChR-mediated autophagic flux
Antioxidants, Vol. 9, Núm. 12, pp. 1-18
-
Melatonin's efficacy in stroke patients; a matter of dose? A systematic review
Toxicology and Applied Pharmacology, Vol. 392
2019
-
New flavonoid–N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 712-727
-
Potential of melatonin as adjuvant therapy of oral cancer in the era of epigenomics
Cancers, Vol. 11, Núm. 11